126 related articles for article (PubMed ID: 16897989)
1. [Combination chemotherapy with S-1 plus CPT-11 for patients with advanced or recurrent colorectal cancer].
Tsunoda A; Nakao K; Kamiyama G; Narita K; Yamazaki K; Watanabe M; Suzuki N; Oonaka T; Kusano M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():135-7. PubMed ID: 16897989
[TBL] [Abstract][Full Text] [Related]
2. [Irinotecan plus oral S-1 in patients with advanced colorectal cancer--biweekly IRIS regimen].
Komatsu Y; Yuki S; Tateyama M; Kudo M; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():131-4. PubMed ID: 16897988
[TBL] [Abstract][Full Text] [Related]
3. A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.
Sadahiro S; Suzuki T; Tanaka A; Okada K; Saito G; Kamijo A
Oncology; 2015; 88(6):353-9. PubMed ID: 25592116
[TBL] [Abstract][Full Text] [Related]
4. [S-1 as a single agent for colorectal cancer].
Eguchi T; Shirao K
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():121-4. PubMed ID: 16897986
[TBL] [Abstract][Full Text] [Related]
5. [The current evidence of S-1 and irinotecan hydrochloride combination chemotherapy with tri-weekly schedule].
Goto A
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():125-30. PubMed ID: 16897987
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.
Higashi D; Egawa Y; Hirano Y; Hirano K; Miyake T; Takahashi H; Uwatoko S; Abe S; Yamamoto S; Mikami K; Futami K; Maekawa T; Inoue R; Miyazaki M
Anticancer Res; 2014 Aug; 34(8):4595-9. PubMed ID: 25075105
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of irinotecan/S-1 combination chemotherapy for patients with oxaliplatin-refractory colorectal cancer.
Oh SY; Ju YT; Choi SK; Ha CY; Lee WS; Kim HG; Lee GW; Kwon HC; Kang JH
Invest New Drugs; 2011 Oct; 29(5):1050-6. PubMed ID: 20238142
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of oral S-1 with irinotecan and bevacizumab (SIRB) as first-line therapy for patients with metastatic colorectal cancer.
Yamada Y; Yamaguchi T; Matsumoto H; Ichikawa Y; Goto A; Kato K; Hamaguchi T; Shimada Y
Invest New Drugs; 2012 Aug; 30(4):1690-6. PubMed ID: 21894500
[TBL] [Abstract][Full Text] [Related]
9. A phase II study evaluating the feasibility of a 5-week cycle of S-1 plus irinotecan (IRIS) in patients with advanced and recurrent colorectal cancer.
Hata T; Fukunaga M; Murata K; Uemura Y; Fukuzaki T; Ota H; Ohue M; Ohnishi T; Tanaka N; Takemasa I; Mizushima T; Ikeda M; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M
Cancer Chemother Pharmacol; 2013 Jun; 71(6):1657-63. PubMed ID: 23543294
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a phase II study of S-1 plus irinotecan in metastatic colorectal cancer.
Iwasa S; Yamada Y; Kato K; Goto A; Honma Y; Hamaguchi T; Shimada Y
Anticancer Res; 2012 Sep; 32(9):4157-61. PubMed ID: 22993378
[TBL] [Abstract][Full Text] [Related]
11. [Current evidence of irinotecan combination chemotherapy with TS-1 in patients with advanced colorectal cancer].
Goto A
Gan To Kagaku Ryoho; 2006 Jul; 33(7):896-900. PubMed ID: 16835475
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Watanabe M; Matsui N; Kusano M
Oncology; 2009; 77(3-4):192-6. PubMed ID: 19729976
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of a 3-week cycle of irinotecan and S-1 in patients with advanced colorectal cancer.
Kusaba H; Esaki T; Futami K; Tanaka S; Fujishima H; Mitsugi K; Sakai K; Ariyama H; Tanaka R; Kinugawa N; Ueki T; Mibu R; Baba E; Nakano S; Akashi K
Cancer Sci; 2010 Dec; 101(12):2591-5. PubMed ID: 21077997
[TBL] [Abstract][Full Text] [Related]
14. [S-1 for gastric cancer-S-1 monotherapy and its progress].
Shitara K; Sakata Y; Kudou T; Munakata M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():43-51. PubMed ID: 16897971
[TBL] [Abstract][Full Text] [Related]
15. [Progress in chemotherapy for colorectal cancer].
Sasaki T; Maeda Y
Gan To Kagaku Ryoho; 2000 Dec; 27(14):2185-92. PubMed ID: 11142161
[TBL] [Abstract][Full Text] [Related]
16. [Second-or third-line chemotherapy with CPT-11+TS-1 for 5 cases of metastatic and recurrent colorectal cancer].
Ogata K; Ohchi T; Doi K; Matsuo A; Kudo K; Ootao R
Gan To Kagaku Ryoho; 2007 Apr; 34(4):627-30. PubMed ID: 17431354
[TBL] [Abstract][Full Text] [Related]
17. Dosage escalation study of S-1 and irinotecan in metronomic chemotherapy against advanced colorectal cancer.
Ogata Y; Sasatomi T; Akagi Y; Ishibashi N; Mori S; Shirouzu K
Kurume Med J; 2009; 56(1-2):1-7. PubMed ID: 20103995
[TBL] [Abstract][Full Text] [Related]
18. Second-line combination chemotherapy of oral S-1 with cisplatin and irinotecan for colorectal cancer resistant to 5-FU.
Tsutsumi S; Yamaguchi S; Ide M; Tsuboi K; Fukasawa T; Yamaki S; Asao T; Kuwano H
Hepatogastroenterology; 2006; 53(68):196-200. PubMed ID: 16608023
[TBL] [Abstract][Full Text] [Related]
19. [Irinotecan plus oral S-1 in patients with advanced gastric cancer-biweekly IRIS regimen].
Komatsu Y; Yuki S; Miyagishima T; Asaka M
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():75-8. PubMed ID: 16897976
[TBL] [Abstract][Full Text] [Related]
20. Phase I study of S-1 combined with irinotecan (CPT-11) in patients with advanced colorectal cancer.
Tsunoda A; Yasuda N; Nakao K; Narita K; Yamazaki K; Watanabe M; Suzuki N; Kusano M
Oncology; 2007; 72(1-2):58-63. PubMed ID: 17998791
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
